Larazotide acetate

立即咨询

Larazotide acetate

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

881851-50-9

包装与价格：

包装	价格(元)
10 mM * 1 mL in Water	电议
1mg	电议
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议

产品名称

醋酸拉瑞唑来

产品介绍

Larazotide acetate 是一种多肽，是具有口服活性的zonulin拮抗剂。Larazotide acetate 对水痘带状疱疹病毒(VZV)具有抗病毒活性，对 OKA 和 07-1 株系的EC₅₀值分别为 44.14 和 59.06 μM。Larazotide acetate 可用于乳糜泻和感染的研究。

生物活性

Larazotide acetate is a peptide which is an orally activezonulinantagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus(VZV)withEC₅₀sof 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease andinfection.

IC₅₀& Target

Paracellular permeability^[1]

体外研究
(In Vitro)

Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth^[1].
Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively^[1].
Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells^[2].
Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells^[2].

Cell Cytotoxicity Assay^[1]

Cell Line:	Vero cell line
Concentration:	1-100 μM
Incubation Time:	5 days
Result:	Inhibited Vero cell growth with an CC₅₀value of 82.5 μM.

体内研究
(In Vivo)

Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice^[1].

Animal Model:	HLA-HCD4/DQ8 double transgenic mice^[2]
Dosage:	250 μg
Administration:	Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:	Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.

Clinical Trial

分子量

785.89

性状

Solid

Formula

C₃₄H₅₉N₉O₁₂

CAS 号

881851-50-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 16.67 mg/mL(21.21 mM;Need ultrasonic)

DMSO : 3.2 mg/mL(4.07 mM;Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	1.2724 mL	6.3622 mL	12.7244 mL
5 mM	0.2545 mL	1.2724 mL	2.5449 mL
10 mM	0.1272 mL	0.6362 mL	1.2724 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (127.24 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。